Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
